text.skipToContent text.skipToNavigation
Pharma & Biotech

P3 Primary Cell 4D-NucleofectorTM X Kit L

Catalog #: V4XP-3024
For efficient transfection of specific primary cells, e.g. human T cells, CD34 or rat neurons, in the 4D-NucleofectorTM X Unit (100 µL format).

Product Overview

The P3 Primary Cell 4D-NucleofectorTM X Kit L is one of our five 4D-NucleofectorTM Kits suited for transfecting primary cells in the 100 µL NucleocuvetteTM Vessel format when working with the 4D-NucleofectorTM X Unit.

This kit has been determined to be optimal for transfecting following cell types: '

  • B cell (human)
  • CD34+ cell (human)
  • Chondrocyte (human)
  • DC (human)
  • DC (mouse), mature
  • ES (human), H9 ES (mouse)
  • Hepatocyte (human)
  • HMEC (human)
  • Keratinocyte (human)
  • Macrophage (human)
  • Monocyte (human)
  • Neuron (rat), brain Hi/Cx
  • NHBE (human)
  • RPE (human)
  • T cell (human), stim.
  • T cell (mouse), unstim.

The respective cell type-specific Optimized Protocols or recommendations are available under "Instructions" or  in our knowledge database. In these Optimized Protocols the best Nucleofection conditions are indicated. In addition, we share our experience and knowledge for treatment of individual cell types.

The kit is available in different variants for either 12 or 24 reactions.


  • High transfection efficiencies for primary cells
  • Cells maintain functionality post transfection
  • Conditions are transferable between 4D-NucleofectorTM System, 96-well ShuttleTM System and 384-well NucleofectorTM System


  • Transfection of cell numbers in the range of 2 x 105 to 2 x 107 cells
  • Low throughput applications

Content & Storage


2.25 mL P3 Primary Cell NucleofectorTM Solution
0.5 mL Supplement 1
50 µg pmaxGFPTM Vector (1 μg/μl in 10 mM Tris pH 8.0)
24 x 100 µL NucleocuvetteTM Vessel
24 x Single use pipettes


Safety Data Sheets (SDS)

Certificate of Analysis (CoA)

Please enter Lot Number, including all zeros, located on the product label and please take into account that it is case sensitive.

Subscribe to our eNewsletter

Keep up to speed on the latest scientific developments, events, tips and tools from Lonza.

CRISPR is Editing its Way Toward Cell and Gene Therapy

Learn about CRISPR from discovery to cell and gene therapies, covering topics such as finding therapeutic pathways or process development considerations for bringing gene edited therapies to the clinic.

Presented by GEN


Knowledge Center

Need technical data?

Browse our Cell and Transfection, Citation, FAQ and Culture Media Technical Databases.

We use cookies to deliver the best service to you. By continuing to browse the site, you are agreeing to our use of cookies.Ok